Table 2. Tumor response to PNP-DTX in each patient.
| Group (Dose) | No | Primary Ds. | Response after 2nd cycle | Maximal Response |
|---|---|---|---|---|
| 1 (20mg/m2) | 11 | Colon | PD | PD |
| 12 | Colon | PD | PD | |
| 13 | Rectum | SD | SD | |
| 14 | Colon | SD | SD | |
| 15 | Colon | SD | SD | |
| 16 | Colon | PD | PD | |
| 2 (35mg/m2) | 21 | Colon | PD | PD |
| 22 | Cervix | PD | PD | |
| 23 | Colon | PD | PD | |
| 3 (45mg/m2) | 31 | Breast | SD | PR |
| 32 | Bladder | SD | SD | |
| 33 | Colon | PD | PD | |
| 4 (60mg/m2) | 41 | Breast | SD | SD |
| 42 | Adrenal | PD | PD | |
| 43 | NSCLC | N/A* | N/A* | |
| 44 | Breast | PR | PR | |
| 45 | Bladder | PR | PR | |
| 46 | Kidney | SD | SD | |
| 5 (75mg/m2) | 51 | Pancreas | SD | PR |
*
Not-available because patient died by unknown cause after 1st cycle of PNP-DTX
PR: Partial remission, SD: Stable disease, PD: Progression of disease